Write a notes on Local Anesthetic toxicity and its management for MD Anaesthesiology exam from Standard books and resources

Reading File

Finding Sources

Reading File

Searching PubMed

"local anesthetic systemic toxicity" AND "lipid emulsion" AND management

Reading File

Excellent. I now have comprehensive content from all major anesthesiology textbooks. Let me compile the comprehensive MD Anaesthesiology exam notes.

LOCAL ANESTHETIC SYSTEMIC TOXICITY (LAST) - MD Anaesthesiology Exam Notes

Sources: Miller's Anesthesia 10e, Barash's Clinical Anesthesia 9e, Morgan & Mikhail's Clinical Anesthesiology 7e, Katzung's Basic & Clinical Pharmacology 16e; ASRA Practice Advisory 2017 (Neal JM et al., Reg Anesth Pain Med 2018;43:113-123)

1. DEFINITION

Local Anesthetic Systemic Toxicity (LAST) refers to the toxic syndrome that results when plasma concentrations of local anesthetics reach levels sufficient to produce deleterious effects on the CNS and cardiovascular system, due to either inadvertent intravascular injection or excessive systemic absorption from the site of administration.

Incidence: ~1:1,000 for nerve stimulator-guided blockade; ~1:1,600 for ultrasound-guided regional anesthesia (Miller's, p. 3604)
CNS is more susceptible than the CVS - toxic blood level for CNS effects is lower than for cardiovascular collapse
Only 60% of patients exhibit the classic sequence of CNS symptoms before cardiovascular collapse; the remaining 40% deviate significantly from this pattern (Miller's, p. 3604)

2. MECHANISMS OF TOXICITY

a. CNS Mechanism

Local anesthetics cross the blood-brain barrier readily. The primary mechanism involves:

Blockade of inhibitory pathways (GABAergic neurons) in the cerebral cortex
Facilitatory (excitatory) neurons then function unopposed → CNS excitation → seizures
With very high doses, both inhibitory and facilitatory circuits are blocked → generalized CNS depression, coma, respiratory arrest
Excitatory amino acid neurotransmitter glutamate pathways also play a role (Miller's, p. 3605)

b. Cardiovascular Mechanism

Block of cardiac voltage-gated sodium channels (Nav1.5) in Purkinje fibers and cardiomyocytes → negative inotropy and arrhythmia
Prolonged recovery time from sodium channel inactivation ("fast in, slow out" kinetics - particularly with bupivacaine)
Inhibition of fatty acid metabolism (mitochondrial respiratory chain disruption)
Interference with calcium and potassium channel homeostasis (Barash, p. 1712)
Bupivacaine causes greater and more persistent Na+ channel blockade than lidocaine because it dissociates very slowly during diastole

3. RISK FACTORS FOR LAST (Katzung, p. 731)

Category	Details
Extremes of age	<4 months (low hepatic clearance, low α₁-acid glycoprotein/AAG); Elderly (low clearance, increased nerve sensitivity)
Pregnancy	Decreased AAG, increased sensitivity (hormonal changes), increased cardiac output → higher absorption rate
Hepatic disease	Reduced AAG and albumin → more free (unbound) drug in plasma; prolonged half-life (e.g., lidocaine t½ rises from 1.5h → 5h in liver disease)
Cardiac failure	Reduced hepatic blood flow → impaired clearance of amide LAs
Renal disease	Metabolic acidosis → rapid rise in plasma LA levels
Low body weight	Equivalent dose has higher mg/kg effect
Acidosis/Hypercapnia	Potentiates both CNS and cardiovascular toxicity (see below)
Concurrent CNS depressants	Mask early warning signs (e.g., sedation during MAC)
L-carnitine deficiency	Enhanced cardiac toxicity via mitochondrial mechanism

Aggravating Factors - Acidosis and Hypercapnia

Hypercapnia increases cerebral blood flow → more LA delivered to brain
Acidosis lowers intraneuronal pH → ion trapping of cationic form → increased apparent CNS toxicity
Acidosis also decreases plasma protein binding of LAs → more free drug available
Seizures themselves produce hypoventilation → combined respiratory and metabolic acidosis → vicious cycle of worsening toxicity (Miller's, p. 3606)

4. SITE OF INJECTION AND ABSORPTION RATE

Systemic absorption varies by injection site (highest to lowest blood levels per unit dose):

Intercostal > Caudal > Epidural > Brachial plexus > Sciatic/femoral > Subcutaneous infiltration

This is clinically important because intercostal blocks carry the highest risk for systemic toxicity even with "safe" doses.

5. CLINICAL PRESENTATION

CNS Toxicity - Dose-Dependent Sequence (Lidocaine plasma concentration model, Barash Table 22-11)

Plasma Lidocaine (mcg/mL)	Clinical Effect
1-5	Analgesia
5-10	Lightheadedness, tinnitus, numbness of tongue, metallic taste
10-15	Seizures, unconsciousness
15-25	Coma, respiratory arrest
>25	Cardiovascular depression

Progression of CNS signs:

Prodromal (excitatory): Perioral tingling/numbness, metallic taste, tinnitus, visual disturbances (difficulty focusing), dizziness, lightheadedness, disorientation
Excitatory phase: Shivering, facial/distal extremity muscle twitching, nystagmus, slurred speech - heralds seizures
Convulsive phase: Generalized tonic-clonic seizures
Depressive phase: CNS depression, respiratory depression/arrest, coma

Note: CNS disturbances are prominent in 80-90% of LAST cases (Barash, p. 1720); prodromal CNS symptoms may be absent in 10-20% of cases which present directly with cardiovascular signs.

Cardiovascular Toxicity

Direct cardiac effects:

Prolonged PR interval, widening of QRS complex
Bradycardia, heart block (partial → complete)
Hypotension (myocardial depression)
Dysrhythmias: SVT → wide complex tachycardia → ventricular fibrillation → asystole
Cardiovascular collapse

Bupivacaine-specific cardiotoxicity:

More potent, more lipid-soluble → binds sodium channels with much higher affinity
"Fast in, slow out" - doesn't dissociate from cardiac channels between beats
Associated with severe, treatment-resistant ventricular arrhythmias and cardiovascular collapse
Ropivacaine and levobupivacaine are 30-40% less cardiotoxic than bupivacaine on a milligram-for-milligram basis (Barash, p. 1710)

Indirect cardiovascular effects:

High neuraxial blockade → sympathectomy → severe hypotension and bradycardia

6. SEQUENCE OF EVENTS IN LAST

The classic sequence is: CNS excitation → CNS depression → Cardiovascular collapse

However, with high-potency agents (bupivacaine) given as rapid IV bolus, cardiovascular collapse may occur simultaneously with or even before CNS manifestations ("cardiovascular collapse without warning").

7. DIFFERENTIAL DIAGNOSIS

Vasovagal reaction
High spinal / total spinal block
Anaphylaxis/allergic reaction
Seizure disorder
Hypoglycemia
Air embolism
Intrathecal opioid toxicity

8. PREVENTION OF LAST

Strict adherence to maximum recommended doses for each drug and each technique
Aspiration test before injection (negative aspiration does not exclude intravascular placement)
Fractional/incremental injection (3-5 mL increments with 30 second intervals)
Test dose: Epinephrine 15 mcg (3 mL of 1:200,000) - heart rate rise of >20 bpm suggests intravascular injection (note: unreliable in patients on beta-blockers)
Ultrasound guidance reduces but does not eliminate LAST risk
Real-time monitoring: ECG, pulse oximetry, BP, verbal contact
Use of epinephrine as additive to slow absorption and serve as marker for inadvertent IV injection
Avoid high-concentration bupivacaine 0.75% for epidural - associated with cardiac arrest cases
Choose ropivacaine or levobupivacaine over bupivacaine where comparable efficacy exists, especially for high-volume blocks

9. MANAGEMENT OF LAST

Step-by-Step Protocol (ASRA Practice Advisory 2017 - Barash Table 22-13)

STEP 1: Call for Help

Alert entire team at first signs of LAST
Activate emergency response

STEP 2: Airway Management

Secure airway and ventilate with 100% oxygen
Prevent/correct hypoxia, hypercapnia, and acidosis
Intubate if necessary
Rationale: Hypoxia and acidosis potentiate both CNS and cardiovascular toxicity; target normocapnia

STEP 3: Administer 20% Lipid Emulsion (Intralipid) - CORNERSTONE OF TREATMENT

Parameter	Dose
Initial bolus	100 mL over 2-3 min (patients >70 kg) OR 1.5 mL/kg over 2-3 min (patients <70 kg)
Infusion	200-250 mL over 15-20 min (>70 kg) OR 0.25 mL/kg/min (<70 kg)
If unstable	Repeat bolus; increase infusion to 0.5 mL/kg/min
Duration	Continue for at least 10 min after restoration of circulatory stability
Upper limit	12 mL/kg as upper limit for initial dosing

Mechanism of lipid emulsion ("lipid sink" theory):

Creates a large lipid compartment in plasma that sequesters (extracts) lipophilic local anesthetics from cardiac and neural tissue
Also proposed: directly supplies fatty acid substrates to cardiac mitochondria (reverses FA metabolism inhibition)
Improves cardiac conduction and function

STEP 4: Seizure Management

Benzodiazepines are first-line (midazolam 1-5 mg IV) - also prevent further LA-induced seizures
Propofol can be used but avoid large doses in hemodynamically unstable patients
Thiopental in small doses is effective but causes more cardiovascular depression
For intractable seizures: small dose succinylcholine to minimize acidosis and hypoxemia from prolonged convulsions
Do NOT use propofol as a substitute for lipid emulsion - it has a lipid vehicle but the concentration is too low and the drug itself causes cardiovascular depression

STEP 5: Cardiovascular Resuscitation - Modified ACLS Algorithm

Drug	Guidance
Epinephrine	Small initial doses (<1 mcg/kg); use incremental dosing - large ACLS doses (1 mg) may worsen dysrhythmias and impair lipid emulsion efficacy
Amiodarone	Preferred for ventricular arrhythmias (especially bupivacaine-induced)
Atropine	For bradycardia

DRUGS TO AVOID:

Vasopressin - avoid (can worsen outcome)
Calcium channel blockers - avoid (additive myocardial depression)
Beta-blockers - avoid (additive myocardial depression)
Local anesthetics as antiarrhythmics (e.g., lidocaine) - avoid (additive toxicity)

STEP 6: Cardiopulmonary Bypass / ECMO

Alert nearest facility with CPB capability if cardiac instability persists
ECMO/CPB should be considered early if the patient does not respond to lipid emulsion + vasopressors
Provides time for LA to redistribute and be metabolized

STEP 7: Post-resuscitation Monitoring

Continue to monitor for at least 2-6 hours after resolution of symptoms
Especially important in patients with significant cardiovascular morbidities
LAST can have biphasic presentation - initial recovery followed by secondary deterioration

10. SPECIFIC TOXICITIES

A. Bupivacaine Cardiotoxicity

Most feared due to refractory nature
Mechanism: extremely high affinity for Nav1.5, very slow dissociation
Avoid 0.75% bupivacaine epidurally
Management: lipid emulsion + amiodarone; CPB if refractory
0.5% is maximum for epidural; obstetric patients most vulnerable

B. Methemoglobinemia (Prilocaine)

Requires 600 mg dose in adults
Hepatic metabolism → O-toluidine → oxidizes Hb to MetHb
Also seen with benzocaine (topical) and dapsone
Clinical: cyanosis unresponsive to O₂, SpO₂ ~85% despite normal PaO₂
Treatment: Methylene blue 1-2 mg/kg IV
Special concern: EMLA cream in neonates with metabolic disorders

C. Transient Neurological Symptoms (TNS)

Also called Transient Radicular Irritation (TRI)
Back pain radiating to legs without motor/sensory deficits
Occurs after resolution of spinal anesthesia, resolves within days
Most common with hyperbaric lidocaine (incidence up to 12%)
Also with tetracaine (2%), bupivacaine (1%), mepivacaine, prilocaine
Risk factors: lithotomy position, outpatient surgery, male gender
Treatment: NSAIDs, conservative management

D. Neurotoxicity / Cauda Equina Syndrome

High concentrations of LAs applied directly to neural tissue cause irreversible block
5% lidocaine via microcatheters for continuous spinal → cauda equina syndrome (historical)
Clinically relevant concentrations are generally safe due to in-situ dilution
Intrafascicular > extrafascicular > extraneural placement in terms of damage risk

E. Allergic Reactions

True allergy is rare
Aminoesters (procaine, tetracaine, benzocaine) more allergenic - metabolized to PABA (p-aminobenzoic acid), known allergen
Aminoamides rarely cause true allergic reactions
Methylparaben preservative in some amide solutions has PABA-like structure
Cross-reactivity: possible between different esters; rare between esters and amides
Anaphylaxis managed with epinephrine, antihistamines, steroids

11. SPECIAL POPULATIONS

Pediatric/Neonatal Considerations

Neonates: prolonged LA infusions must not exceed bupivacaine 0.2 mg/kg/h (even this may approach toxic range at 48h in young infants)
Lidocaine infusions in neonates: ≤0.8 mg/kg/h; accumulation of MEGX metabolite can cause seizures
Chloroprocaine preferred for epidural infusion in neonates (rapidly cleared)
Lipid emulsion rescue is safe and effective in neonates

Pregnancy

Reduced AAG → more free LA
Increased sensitivity due to hormonal changes
Avoid 0.75% epidural bupivacaine (historical cardiac arrest cases)
LAST treatment is the same including lipid emulsion + modified ACLS

Elderly / Hepatic/Renal Disease

Reduce doses
More stringent monitoring
Lower threshold for treating mild symptoms

12. PREPARATION AND VIGILANCE

Every clinician performing regional anesthesia should have immediately available (Miller's, p. 3606):

Monitoring equipment (ECG, pulse oximetry, BP)
Oxygen source
Rescue airway equipment
Drugs to terminate convulsions (midazolam, propofol, thiopental)
20% lipid emulsion pre-drawn and ready
Epinephrine in appropriate doses
IV access secured before any block

13. KEY EXAM POINTS SUMMARY

Point	Detail
Most common cause of LAST	Inadvertent intravascular injection
Highest systemic absorption site	Intercostal block
First symptom of LAST	Perioral numbness/tingling, metallic taste
CNS:CVS toxicity ratio	CNS occurs at lower blood levels; CVS at higher
Most cardiotoxic LA	Bupivacaine (slow dissociation from Na channels)
Safer alternatives to bupivacaine	Ropivacaine, Levobupivacaine (30-40% less cardiotoxic)
Cornerstone of LAST management	20% lipid emulsion (Intralipid)
Lipid emulsion bolus dose	1.5 mL/kg (or 100 mL if >70 kg) over 2-3 min
Lipid emulsion mechanism	"Lipid sink" - sequesters LA from cardiac tissue
Seizure drug of choice	Benzodiazepine (midazolam 1-5 mg)
Cardiac arrhythmia drug	Amiodarone
Drugs to avoid in LAST	Vasopressin, Ca-channel blockers, beta-blockers
Epinephrine in LAST	Small doses <1 mcg/kg (not standard 1 mg ACLS dose)
Prilocaine-specific toxicity	Methemoglobinemia; treat with methylene blue
Treatment of methemoglobinemia	Methylene blue 1-2 mg/kg IV
Post-LAST monitoring	At least 2-6 hours
If refractory to treatment	Cardiopulmonary bypass / ECMO
LA least likely to cause true allergy	Amide group (lidocaine, bupivacaine, etc.)
TNS most commonly caused by	Hyperbaric lidocaine intrathecally (up to 12% incidence)

14. MAXIMUM RECOMMENDED DOSES (Barash Table 22-9)

Drug	Without Epinephrine (mg)	With Epinephrine (mg)
Lidocaine	300	500
Bupivacaine	175	225
Levobupivacaine	150	150
Mepivacaine	400	500
Ropivacaine	200-250	N/A
Etidocaine	300	400

Note: These are general maxima - site of injection and patient factors may mandate lower doses

References

Miller RD, et al. Miller's Anesthesia, 10th ed. Elsevier; 2023. (Chapter on Local Anesthetics, pp. 3603-3618)
Barash PG, et al. Barash, Cullen, and Stoelting's Clinical Anesthesia, 9th ed. Wolters Kluwer; 2022. (Chapter 22, pp. 1707-1722)
Morgan GE, Mikhail MS. Morgan and Mikhail's Clinical Anesthesiology, 7th ed. McGraw Hill; 2022. (pp. 1854-1856)
Katzung BG. Basic and Clinical Pharmacology, 16th ed. McGraw Hill; 2021. (pp. 729-732)
Neal JM, et al. The Third American Society of Regional Anesthesia and Pain Medicine (ASRA) Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. Reg Anesth Pain Med. 2018;43:113-123.

This is a shared conversation. Sign in to Orris to start your own chat.